Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | ZYBT Zhengye Biotechnology Holding Limited | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $1.26 +5.0% | $15.90 -2.5% |
| StockIQ Score | 42D Weak Risk: High | 41D Weak Risk: High |
| Technical | 21F | 36F |
| Fundamental | — | 35F |
| Growth | — | 50C- |
| Fair Value | — | 38F |
| News | 100A+ | 50C- |
| Quality | — | 50C- |
| Risk | 34F | 40D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
ZYBT has a slightly higher investor score (42 vs. 41) but both stocks share the same "WEAK" rating. AAPG outperforms ZYBT significantly in technical (36 vs. 21), fundamental (35 vs. unavailable), growth (50 vs. unavailable), and valuation (38 vs. unavailable) scores, making it stronger across all available metrics.
